Vyome Holdings, Inc (HIND) stock
HINDNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.58−0.05 (-3.07%)
Close on Nov 13, 2026Market cap $11.09MP/E –Yield –
Vyome EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Vyome's EPS for the twelve months ending Sep 30, 2023 was -$464990.53. For fiscal 2025 it was -$4.86. The highest annual figure on record is -$4.86 in fiscal 2025.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$4.86 | – |
| FY2024 | Dec 31, 2024 | -$6001.39 | – |
| FY2023 | Dec 31, 2023 | -$22284.87 | – |
| FY2022 | Dec 31, 2022 | -$1269556.20 | – |
| FY2021 | Dec 31, 2021 | -$3368812.26 | – |
| FY2020 | Dec 31, 2020 | -$3235095.00 | – |
| FY2019 | Dec 31, 2019 | -$2931987.00 | – |
| FY2018 | Dec 31, 2018 | -$11448156.00 | – |
| FY2017 | Dec 31, 2017 | -$12124320.00 | – |
| FY2016 | Dec 31, 2016 | -$28270650.00 | – |
| FY2015 | Dec 31, 2015 | -$158199060.00 | – |
| FY2014 | Dec 31, 2014 | -$108477690.00 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.13 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.10 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.15 | – |
| Q3 FY2025 | Sep 30, 2025 | -$3.06 | – |
| Q2 FY2025 | Jun 30, 2025 | -$799.90 | – |
| Q1 FY2025 | Mar 31, 2025 | -$761.59 | – |
| Q3 FY2024 | Sep 30, 2024 | -$285239.10 | – |
| Q2 FY2024 | Jun 30, 2024 | -$18403.56 | – |
| Q1 FY2024 | Mar 31, 2024 | -$27209.37 | – |
| Q3 FY2023 | Sep 30, 2023 | -$11931.36 | – |
| Q2 FY2023 | Jun 30, 2023 | -$12590.64 | – |
| Q1 FY2023 | Mar 31, 2023 | -$18186.48 | – |
| Q4 FY2022 | Dec 31, 2022 | -$422282.05 | – |
| Q3 FY2022 | Sep 30, 2022 | -$314882.58 | – |
| Q2 FY2022 | Jun 30, 2022 | -$285038.10 | – |
| Q1 FY2022 | Mar 31, 2022 | -$254960.46 | – |
| Q4 FY2021 | Dec 31, 2021 | -$1201580.65 | – |
| Q3 FY2021 | Sep 30, 2021 | -$584415.54 | – |
| Q2 FY2021 | Jun 30, 2021 | -$497796.60 | – |
| Q1 FY2021 | Mar 31, 2021 | -$721397.04 | – |
| Q4 FY2020 | Dec 31, 2020 | -$1219428.57 | – |
| Q3 FY2020 | Sep 30, 2020 | -$769428.00 | – |
| Q2 FY2020 | Jun 30, 2020 | -$542097.00 | – |
| Q1 FY2020 | Mar 31, 2020 | -$396372.00 | – |
| Q3 FY2019 | Sep 30, 2019 | -$355569.00 | – |
| Q2 FY2019 | Jun 30, 2019 | -$1468908.00 | – |
| Q1 FY2019 | Mar 31, 2019 | -$2092611.00 | – |
| Q4 FY2018 | Dec 31, 2018 | -$2273310.00 | – |
| Q3 FY2018 | Sep 30, 2018 | -$2022663.00 | – |
| Q2 FY2018 | Jun 30, 2018 | -$3322530.00 | – |
| Q1 FY2018 | Mar 31, 2018 | -$4138590.00 | – |
| Q4 FY2017 | Dec 31, 2017 | -$3497400.00 | – |
| Q3 FY2017 | Sep 30, 2017 | -$3205950.00 | – |
| Q2 FY2017 | Jun 30, 2017 | -$2681340.00 | – |
| Q1 FY2017 | Mar 31, 2017 | -$2739630.00 | – |
| Q4 FY2016 | Dec 31, 2016 | -$2972790.00 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?